China Oncology ›› 2023, Vol. 33 ›› Issue (7): 701-706.doi: 10.19401/j.cnki.1007-3639.2023.07.008
• Review • Previous Articles Next Articles
ZHANG Haoting1(), ZHENG Jing2, FU Mengjiao2, ZHOU Jianying2()
Received:
2022-10-08
Revised:
2022-11-24
Online:
2023-07-30
Published:
2023-08-10
Contact:
ZHOU Jianying.
CLC Number:
ZHANG Haoting, ZHENG Jing, FU Mengjiao, ZHOU Jianying. Research progress on thyroid dysfunction induced by immunotherapy for lung cancer[J]. China Oncology, 2023, 33(7): 701-706.
Tab. 1
Comparison of irTD in lung cancer patients in various clinical trials"
Clinical trial | Histological subtype | Case N | Treatment | Incidence of irTD all grade/% | Incidence of irTD grade 3%-5/% | ||||
---|---|---|---|---|---|---|---|---|---|
Hypo-thyroidism | Hyper-thyroidism | Thyroiditis | Hypo-thyroidism | Hyper-thyroidism | Thyroiditis | ||||
Checkmate-057[ | Non-squamous NSCLC | 292 | Nivolumab | 7.0 | 1.0 | 0.3 | 0.0 | 0.0 | 0.0 |
Checkmate-017[ | Squamous NSCLC | 135 | Nivolumab | 4.0 | NA | NA | 0.0 | NA | NA |
Keynote-024[ | NSCLC | 154 | Pembrolizumab | 9.1 | 7.8 | 2.6 | 0.0 | 0.0 | 0.0 |
Checkmate-026[ | NSCLC | 267 | Nivolumab | 6.4 | NA | NA | 0.0 | NA | NA |
Keynote-042[ | NSCLC | 636 | Pembrolizumab | 12.0 | 6.0 | 2.0 | 0.2 | 0.2 | 0.0 |
Keynote-042[ | NSCLC | 128 | Pembrolizumab | 11.7 | 5.5 | 1.6 | 0.0 | 0.8 | 0.0 |
CheckMate 078[ | NSCLC | 337 | Nivolumab | 4.0 | 3.0 | 0.3 | 0.0 | 0.0 | 0.0 |
Antonia, et al[ | NSCLC | 476 | Durvalumab | 9.5 | 2.7 | NA | 0.2 | 0.0 | NA |
JAVELIN Lung 200[ | NSCLC | 396 | Avelumab | 5.0 | 1.0 | 0.3 | 0.3 | NA | NA |
Keynote-407[ | Squamous NSCLC | 278 | Pembrolizumab + carboplatin + nab-paclitaxel | 7.9 | 7.2 | 1.1 | 0.4 | 0.4 | 0.4 |
Keynote-189[ | Non-squamous NSCLC | 405 | Pembrolizumab + platinum + pemetrexed | 6.7 | 4.0 | 0.2 | 0.5 | 0.0 | 0.0 |
IMpower130[ | Non-squamous NSCLC | 473 | Atezolizumab + carboplatin + nab-paclitaxel | 11.2 | 4.9 | NA | 0.4 | 0.2 | NA |
IMpower132[ | Non-squamous NSCLC | 292 | Atezolizumab + carboplatin/cisplatin + pemetrexed | 8.2 | 2.4 | NA | 0.3 | 0.3 | NA |
CASPIAN[ | ES-SCLC | 265 | Durvalumab + platinum + etoposide | 9.0 | 8.0 | NA | 0.0 | 0.0 | NA |
IMpower133[ | ES-SCLC | 198 | Atezolizumab + carboplatin + etoposide | 12.6 | 5.6 | NA | 0.0 | 0.0 | NA |
Checkmate-227[ | NSCLC | 396 | Nivolumab + ipilimumab | 11.6 | NA | NA | 0.3 | NA | NA |
396 | Nivolumab | 6.4 | NA | NA | 0.3 | NA | NA | ||
Checkmate-9LA[ | NSCLC | 358 | Nivolumab + ipilimumab + platinum | 16.0 | NA | NA | 0.3 | NA | NA |
Keynote-598[ | NSCLC | 282 | Pembrolizumab + ipilimumab | 15.2 | 8.9 | 1.8 | 0.4 | 0.4 | 0.4 |
281 | Pembrolizumab | 12.1 | 6.0 | 1.1 | 0.4 | 0.0 | 0.0 | ||
Checkmate-032[ | SCLC | 96 | Nivolumab + ipilimumab | 8.3 | 7.3 | NA | 0.0 | 1.0 | NA |
147 | Nivolumab | 4.1 | 2.0 | NA | 0.0 | 0.0 | NA |
[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.v71.3 |
[2] | 周彩存, 王洁, 王宝成, 等. 中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2020年版)[J]. 中国肺癌杂志, 2021, 24(4): 217-235. |
ZHOU C C, WANG J, WANG B C, et al. Chinese experts consensus on immune checkpoint inhibitors for non-small cell lung cancer (2020 version)[J]. Chin J Lung Cancer, 2021, 24(4): 217-235. | |
[3] |
BORGHAEI H, PAZ-ARES L, HORN L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639.
doi: 10.1056/NEJMoa1507643 |
[4] |
BRAHMER J, RECKAMP K L, BAAS P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2): 123-135.
doi: 10.1056/NEJMoa1504627 |
[5] |
MOK T S K, WU Y L, KUDABA I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019, 393(10183): 1819-1830.
doi: 10.1016/S0140-6736(18)32409-7 |
[6] |
READY N E, OTT P A, HELLMANN M D, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort[J]. J Thorac Oncol, 2020, 15(3): 426-435.
doi: S1556-0864(19)33531-2 pmid: 31629915 |
[7] |
HELLMANN M D, PAZ-ARES L, BERNABE CARO R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer[J]. N Engl J Med, 2019, 381(21): 2020-2031.
doi: 10.1056/NEJMoa1910231 |
[8] | CARBONE D P. First-line nivolumab in stage Ⅳ or recurrent non-small cell lung cancer[J]. Oncol Times, 2017, 39(17): 28-29. |
[9] |
RECK M, RODRÍGUEZ-ABREU D, ROBINSON A G, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer[J]. N Engl J Med, 2016, 375(19): 1823-1833.
doi: 10.1056/NEJMoa1606774 |
[10] |
WU Y L, LU S, CHENG Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase Ⅲ clinical trial[J]. J Thorac Oncol, 2019, 14(5): 867-875.
doi: 10.1016/j.jtho.2019.01.006 |
[11] |
WU Y L, ZHANG L, FAN Y, et al. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer: KEYNOTE-042 China study[J]. Int J Cancer, 2021, 148(9): 2313-2320.
doi: 10.1002/ijc.v148.9 |
[12] |
ANTONIA S J, VILLEGAS A, DANIEL D, et al. Durvalumab after chemoradiotherapy in stage Ⅲ non-small cell lung cancer[J]. N Engl J Med, 2017, 377(20): 1919-1929.
doi: 10.1056/NEJMoa1709937 |
[13] |
BARLESI F, VANSTEENKISTE J, SPIGEL D, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study[J]. Lancet Oncol, 2018, 19(11): 1468-1479.
doi: 10.1016/S1470-2045(18)30673-9 |
[14] |
GANDHI L, RODRÍGUEZ-ABREU D, GADGEEL S, et al. Pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer[J]. N Engl J Med, 2018, 378(22): 2078-2092.
doi: 10.1056/NEJMoa1801005 |
[15] |
NISHIO M, BARLESI F, WEST H, et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial[J]. J Thorac Oncol, 2021, 16(4): 653-664.
doi: 10.1016/j.jtho.2020.11.025 |
[16] |
PAZ-ARES L, DVORKIN M, CHEN Y B, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394(10212): 1929-1939.
doi: 10.1016/S0140-6736(19)32222-6 |
[17] |
PAZ-ARES L, LUFT A, VICENTE D, et al. Pembrolizumab plus chemotherapy for squamous non-small cell lung cancer[J]. N Engl J Med, 2018, 379(21): 2040-2051.
doi: 10.1056/NEJMoa1810865 |
[18] |
WEST H, MCCLEOD M, HUSSEIN M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(7): 924-937.
doi: 10.1016/S1470-2045(19)30167-6 |
[19] |
BOYER M, ŞENDUR M A N, RODRÍGUEZ-ABREU D, et al. Pembrolizumab plus ipilimumab or placebo for metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥ 50%: randomized, double-blind phase Ⅲ KEYNOTE-598 study[J]. J Clin Oncol, 2021, 39(21): 2327-2338.
doi: 10.1200/JCO.20.03579 |
[20] |
HORN L, MANSFIELD A S, SZCZĘSNA A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small cell lung cancer[J]. N Engl J Med, 2018, 379(23): 2220-2229.
doi: 10.1056/NEJMoa1809064 |
[21] |
PROF, LUIS, PAZ-ARES, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(2): 198-211.
doi: 10.1016/S1470-2045(20)30641-0 |
[22] | National Cancer Institute. Protocol development cancer therapy evaluation program[EB/OL]. (2017-11-27)[2023-04-28]. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. |
[23] |
KHAN U, RIZVI H, SANO D, et al. Nivolumab induced myxedema crisis[J]. J Immunother Cancer, 2017, 5: 13.
doi: 10.1186/s40425-017-0213-x pmid: 28239466 |
[24] |
ZHOU N, VELEZ M A, BACHRACH B, et al. Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC[J]. Lung Cancer, 2021, 161: 34-41.
doi: 10.1016/j.lungcan.2021.08.009 pmid: 34507111 |
[25] |
YAMAZAKI H, IWASAKI H, YAMASHITA T, et al. Potential risk factors for nivolumab-induced thyroid dysfunction[J]. In Vivo, 2017, 31(6): 1225-1228.
pmid: 29102951 |
[26] |
OSORIO J C, NI A, CHAFT J E, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small cell lung cancer[J]. Ann Oncol, 2017, 28(3): 583-589.
doi: 10.1093/annonc/mdw640 |
[27] |
KOTWAL A, GUSTAFSON M P, BORNSCHLEGL S, et al. Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations[J]. Thyroid, 2020, 30(10): 1440-1450.
doi: 10.1089/thy.2020.0075 |
[28] |
TORIMOTO K, OKADA Y, NAKAYAMADA S, et al. Anti-PD-1 antibody therapy induces Hashimoto’s disease with an increase in peripheral blood follicular helper T cells[J]. Thyroid, 2017, 27(10): 1335-1336.
doi: 10.1089/thy.2017.0062 |
[29] |
KIMBARA S, FUJIWARA Y, IWAMA S, et al. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab[J]. Cancer Sci, 2018, 109(11): 3583-3590.
doi: 10.1111/cas.2018.109.issue-11 |
[30] |
YAMAUCHI I, YASODA A, MATSUMOTO S, et al. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab[J]. PLoS One, 2019, 14(5): e0216954.
doi: 10.1371/journal.pone.0216954 |
[31] |
SABINI E, SFRAMELI A, MARINÒ M. A case of drug-induced Graves’ orbitopathy after combination therapy with tremelimumab and durvalumab[J]. J Endocrinol Invest, 2018, 41(7): 877-878.
doi: 10.1007/s40618-018-0906-0 |
[32] |
ZHAN L, FENG H F, LIU H Q, et al. Immune checkpoint inhibitors-related thyroid dysfunction: epidemiology, clinical presentation, possible pathogenesis, and management[J]. Front Endocrinol (Lausanne), 2021, 12: 649863.
doi: 10.3389/fendo.2021.649863 |
[33] |
MAZARICO I, CAPEL I, GIMÉNEZ-PALOP O, et al. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors[J]. J Endocrinol Invest, 2019, 42(12): 1443-1450.
doi: 10.1007/s40618-019-01058-x pmid: 31093955 |
[34] |
YAMAUCHI I, SAKANE Y, FUKUDA Y, et al. Clinical features of nivolumab-induced thyroiditis: a case series study[J]. Thyroid, 2017, 27(7): 894-901.
doi: 10.1089/thy.2016.0562 pmid: 28537531 |
[35] |
DELIVANIS D A, GUSTAFSON M P, BORNSCHLEGL S, et al. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms[J]. J Clin Endocrinol Metab, 2017, 102(8): 2770-2780.
doi: 10.1210/jc.2017-00448 pmid: 28609832 |
[36] |
KURIMOTO C, INABA H, ARIYASU H, et al. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors[J]. Cancer Sci, 2020, 111(5): 1468-1477.
doi: 10.1111/cas.v111.5 |
[37] |
KRIEG C, NOWICKA M, GUGLIETTA S, et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy[J]. Nat Med, 2018, 24(2): 144-153.
doi: 10.1038/nm.4466 pmid: 29309059 |
[38] |
MAEKURA T, NAITO M, TAHARA M, et al. Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer[J]. In Vivo, 2017, 31(5): 1035-1039.
pmid: 28882978 |
[39] |
YOON J H, HONG A R, KIM H K, et al. Characteristics of immune-related thyroid adverse events in patients treated with PD-1/PD-L1 inhibitors[J]. Endocrinol Metab (Seoul), 2021, 36(2): 413-423.
doi: 10.3803/EnM.2020.906 pmid: 33820396 |
[40] | DE FILETTE J, ANDREESCU C E, COOLS F, et al. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors[J]. Horm Metab, 2019, 51(3): 145-156. |
[41] |
KOTWAL A, KOTTSCHADE L, RYDER M. PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients[J]. Thyroid, 2020, 30(2): 177-184.
doi: 10.1089/thy.2019.0250 pmid: 31813343 |
[42] |
CAMPREDON P, MOULY C, LUSQUE A, et al. Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: retrospective study of 105 patients[J]. Presse Med, 2019, 48(4): e199-e207.
doi: 10.1016/j.lpm.2018.10.019 |
[43] | POLLACK R, ASHASH A, CAHN A, et al. Immune checkpoint inhibitor-induced thyroid dysfunction is associated with higher body mass index[J]. J Clin Endocrinol Metab, 2020, 105(10): dgaa458. |
[44] |
D'AIELLO A, LIN J, GUCALP R, et al. Thyroid dysfunction in lung cancer patients treated with immune checkpoint inhibitors (ICIs): outcomes in a multiethnic urban cohort[J]. Cancers (Basel), 2021, 13(6): 1464.
doi: 10.3390/cancers13061464 |
[45] | 彭智, 袁家佳, 王正航, 等. ASCO/NCCN免疫治疗毒性管理指南解读[J]. 肿瘤综合治疗电子杂志, 2018, 4(2): 38-47. |
PENG Z, YUAN J J, WANG Z H, et al. Comments on ASCO/NCCN management guidelines of toxicities from immunotherapy[J]. J Multidiscip Cancer Manag Electron Version, 2018, 4(2): 38-47. |
[1] | ZHANG Lingling, WANG Xiangyi, WEI Xing, LIN Li, TANG Chuanhao, LIANG Jun. A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis [J]. China Oncology, 2023, 33(8): 776-781. |
[2] | ZUO Xueliang, CHEN Zhiqiang, DONG Runyu, WANG Zhixiong, CAI Juan. The value of combined detection of LDHA and PD-L1 in predicting the efficacy and prognosis of advanced gastric cancer patients treated with PD-1 inhibitor [J]. China Oncology, 2023, 33(5): 460-468. |
[3] | WU Jing, ZHOU Juan, SU Chunxia. Advances in fatty acid metabolism reprogramming of lung cancer [J]. China Oncology, 2023, 33(5): 517-526. |
[4] | SU Chunxia, ZHOU Caicun. Important clinical research progress in lung cancer in 2022 [J]. China Oncology, 2023, 33(3): 218-227. |
[5] | ZOU Chunyuan, XU Xiaofeng, LU Renquan, GUO Lin. Detection of p53, PGP9.5, SOX2, GAGE7, GBU4-5 and MAGE A1 protein levels in lung cancer tissues and peripheral blood and their clinical value [J]. China Oncology, 2023, 33(1): 36-44. |
[6] | XU Yuchen, CHENG Leilei, WANG Yan, LIN Jinyi, CHEN Jiahui, CHEN Yifan, ZHOU Yuhong, LIU Tianshu, GE Junbo. Predictive value of sST2 level in immune-related adverse events [J]. China Oncology, 2022, 32(8): 712-718. |
[7] | HE Liyuan, WANG Yudong. Research progress of ALK kinase domain drug resistance mutation and its future countermeasures [J]. China Oncology, 2022, 32(8): 736-746. |
[8] | HONG Yaping, HUANG Yunjian, HUANG Zhangzhou, CHEN Shengjia, ZHONG Qiaofeng, ZENG Hongfu, ZHUANG Wu. Efficacy and prognostic predictors of first-generation EGFR TKI-targeted therapy in patients with EGFR-mutated advanced non-small cell lung cancer [J]. China Oncology, 2022, 32(7): 624-634. |
[9] | WU Jianhui, CHU Xiangling, WANG Liqiang, LIN Xinqing, XIE Xiaohong, XIE Mengqing, ZHAO Jing, DENG Haiyi, YANG Yilin, QIU Guihuan, ZHOU Maolin, SUN Ni, LI Ru, CHEN Ying, DENG Jiaxi, ZENG Chen, PAN Bolin, QIN Yinyin, LIU Ming, SU Chunxia, ZHOU Chengzhi. Epidemiological analysis of real-world immune checkpoint inhibitor-related pneumonitis in Chinese patients with lung cancer [J]. China Oncology, 2022, 32(6): 469-477. |
[10] | SU Chunxia, ZHOU Caicun. Current status and future directions of immunotherapy for advanced non-small cell lung cancer [J]. China Oncology, 2022, 32(6): 478-486. |
[11] | YU Silai, NI Jianjiao, ZHU Zhengfei. Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects [J]. China Oncology, 2022, 32(6): 487-498. |
[12] | JIANG Jianyun, YING Hongmei. Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma [J]. China Oncology, 2022, 32(5): 445-450. |
[13] | FU Yuanyuan, HOU Runping, FU Xiaolong. Research progress in predicting the risk of lymphatic or hematologic metastasis based on chest CT in early non-small cell lung cancer [J]. China Oncology, 2022, 32(4): 343-350. |
[14] | WANG Zezhou , ZHANG Yang , MO Miao , YUAN Jing , ZHOU Changming , SHEN Jie , FENG Xiaoshuang , WU Haoxuan , LI Hang , YE Ting , HU Hong , CHEN Haiquan , ZHENG Ying . Distribution of metastatic sites and survival analysis of patients with non-metastatic lung cancer at initial diagnosis based on hospital registration [J]. China Oncology, 2021, 31(9): 775-782. |
[15] | LU Li, LU Renquan, SUN Jiajun, LU Ning, GUO Lin. The application of serum N-MID in auxiliary diagnosis and therapeutic effect monitoring of bone metastasis in patients with primary lung cancer [J]. China Oncology, 2021, 31(9): 838-844. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd